135 related articles for article (PubMed ID: 19565925)
1. Design and testing of novel oncolytic vaccinia strains.
Thorne SH
Methods Mol Biol; 2009; 542():635-47. PubMed ID: 19565925
[TBL] [Abstract][Full Text] [Related]
2. Next-generation oncolytic vaccinia vectors.
Thorne SH
Methods Mol Biol; 2012; 797():205-15. PubMed ID: 21948478
[TBL] [Abstract][Full Text] [Related]
3. Vaccinia virus and oncolytic virotherapy of cancer.
Thorne SH; Hwang TH; Kirn DH
Curr Opin Mol Ther; 2005 Aug; 7(4):359-65. PubMed ID: 16121702
[TBL] [Abstract][Full Text] [Related]
4. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
[TBL] [Abstract][Full Text] [Related]
5. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers.
Haddad D; Chen N; Zhang Q; Chen CH; Yu YA; Gonzalez L; Aguilar J; Li P; Wong J; Szalay AA; Fong Y
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S665-74. PubMed ID: 22258815
[TBL] [Abstract][Full Text] [Related]
6. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.
Kirn DH; Wang Y; Le Boeuf F; Bell J; Thorne SH
PLoS Med; 2007 Dec; 4(12):e353. PubMed ID: 18162040
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic vaccinia virus: from bedside to benchtop and back.
Thorne SH
Curr Opin Mol Ther; 2008 Aug; 10(4):387-92. PubMed ID: 18683104
[TBL] [Abstract][Full Text] [Related]
8. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.
McCart JA; Ward JM; Lee J; Hu Y; Alexander HR; Libutti SK; Moss B; Bartlett DL
Cancer Res; 2001 Dec; 61(24):8751-7. PubMed ID: 11751395
[TBL] [Abstract][Full Text] [Related]
9. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
[TBL] [Abstract][Full Text] [Related]
10. Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent.
Gentschev I; Stritzker J; Hofmann E; Weibel S; Yu YA; Chen N; Zhang Q; Bullerdiek J; Nolte I; Szalay AA
Cancer Gene Ther; 2009 Apr; 16(4):320-8. PubMed ID: 18949014
[TBL] [Abstract][Full Text] [Related]
11. Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice.
Chen NG; Yu YA; Zhang Q; Szalay AA
J Transl Med; 2011 Sep; 9():164. PubMed ID: 21951588
[TBL] [Abstract][Full Text] [Related]
12. Enhancing poxvirus oncolytic effects through increased spread and immune evasion.
Kirn DH; Wang Y; Liang W; Contag CH; Thorne SH
Cancer Res; 2008 Apr; 68(7):2071-5. PubMed ID: 18381410
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
Lun XQ; Jang JH; Tang N; Deng H; Head R; Bell JC; Stojdl DF; Nutt CL; Senger DL; Forsyth PA; McCart JA
Clin Cancer Res; 2009 Apr; 15(8):2777-88. PubMed ID: 19351762
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic cancer therapy with a vaccinia virus strain.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B; Hu Z
Oncol Rep; 2019 Jan; 41(1):686-692. PubMed ID: 30365140
[TBL] [Abstract][Full Text] [Related]
15. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus.
Zhang Q; Yu YA; Wang E; Chen N; Danner RL; Munson PJ; Marincola FM; Szalay AA
Cancer Res; 2007 Oct; 67(20):10038-46. PubMed ID: 17942938
[TBL] [Abstract][Full Text] [Related]
16. JNK-deficiency enhanced oncolytic vaccinia virus replication and blocked activation of double-stranded RNA-dependent protein kinase.
Hu W; Hofstetter W; Guo W; Li H; Pataer A; Peng HH; Guo ZS; Bartlett DL; Lin A; Swisher SG; Fang B
Cancer Gene Ther; 2008 Sep; 15(9):616-24. PubMed ID: 18535619
[TBL] [Abstract][Full Text] [Related]
17. Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1.
Huang B; Sikorski R; Kirn DH; Thorne SH
Gene Ther; 2011 Feb; 18(2):164-72. PubMed ID: 20739958
[TBL] [Abstract][Full Text] [Related]
18. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2.
Guo ZS; Naik A; O'Malley ME; Popovic P; Demarco R; Hu Y; Yin X; Yang S; Zeh HJ; Moss B; Lotze MT; Bartlett DL
Cancer Res; 2005 Nov; 65(21):9991-8. PubMed ID: 16267024
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antitumor effects of immune cell-viral biotherapy.
Thorne SH; Negrin RS; Contag CH
Science; 2006 Mar; 311(5768):1780-4. PubMed ID: 16556847
[TBL] [Abstract][Full Text] [Related]
20. In vivo murine tumor gene delivery and expression by systemic recombinant vaccinia virus encoding interleukin-1beta.
Peplinski GR; Tsung AK; Casey MJ; Meko JB; Fredrickson TN; Buller RM; Norton JA
Cancer J Sci Am; 1996; 2(1):21-7. PubMed ID: 9166494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]